Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Pre-hospital Administration of Thrombolytic Therapy With Urgent Culprit Artery Revascularization
NCT00178620 · View on ClinicalTrials.gov ↗
Study Summary
The PATCAR study has been designed to test the hypothesis that the strategy of pre-hospital use of a "clot busting" (thrombolytic) drug followed with emergent heart catheterization including stenting of the problematic coronary artery, will result in a lower mortality and reduced repeat heart attack rates. Early identifying and treating heart attacks patients prior to the arriving at the hospital, in those patients who qualify for the "clot busting" drugs will lower the size of the heart attack damage. This smaller heart attack will lead to fewer problems with less repeat heart attacks and death in the future.
Conditions Studied
Interventions
- DRUG Reteplase 10 Units (U) plus a second dose of reteplase 10 U
- DRUG Reteplase 10 U
- PROCEDURE Urgent Percutaneous Coronary Intervention (PCI)
- PROCEDURE Primary Percutaneous Coronary Intervention (PCI)
Study Locations (1)
Texas
- Memorial Hermann Hospital / The University of Texas HSC — Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 390 participants |
| Start Date | 2003-09 |
| Est. Completion | 2009-12 |
| Phase | Phase 4 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00178620
The ClinicalTrials.gov registry entry for NCT00178620 describes a study currently listed as completed. It is categorized as Phase 4, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 390 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 811 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 3 conditions, with Myocardial Infarction appearing as the primary indexed condition, and to 4 interventions — of which Reteplase 10 Units (U) plus a second dose of reteplase 10 U is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00178620 reports 1 study location spanning 1 distinct geographic area — top geographies include Texas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00178620 about?
NCT00178620 is a clinical study titled "Pre-hospital Administration of Thrombolytic Therapy With Urgent Culprit Artery Revascularization". The PATCAR study has been designed to test the hypothesis that the strategy of pre-hospital use of a "clot busting" (thrombolytic) drug followed with emergent heart catheterization including stenting of the problematic coronary artery, will result in a lower mortality and reduced repeat heart attack...
What is the current status of trial NCT00178620?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 390 participants. The study started on 2003-09. Estimated completion is 2009-12.
What conditions does trial NCT00178620 study?
This clinical trial studies the following conditions: Myocardial Infarction, Heart Disease, Acute Myocardial Infarction. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00178620?
The interventions under investigation include: Reteplase 10 Units (U) plus a second dose of reteplase 10 U (DRUG), Reteplase 10 U (DRUG), Urgent Percutaneous Coronary Intervention (PCI) (PROCEDURE), Primary Percutaneous Coronary Intervention (PCI) (PROCEDURE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00178620?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 811 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00178620 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.